Share-based Payment Arrangement, Expense of ARS Pharmaceuticals, Inc. from 31 Mar 2020 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ARS Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 31 Dec 2024.
  • ARS Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2024 was $4,263,000, a 87% increase year-over-year.
  • ARS Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2024 was $14,534,000, a 57% increase year-over-year.
  • ARS Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $14,534,000, a 57% increase from 2023.
  • ARS Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $9,235,000, a 58% increase from 2022.
  • ARS Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $5,843,000, a 107% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

ARS Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $14,534,000 $4,263,000 +$1,985,000 +87% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
Q3 2024 $12,549,000 $3,591,000 +$982,000 +38% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 $11,567,000 $3,365,000 +$1,267,000 +60% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2024 2024 Q2
Q1 2024 $10,300,000 $3,315,000 +$1,065,000 +47% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $9,235,000 $2,278,000 -$2,485,000 -52% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 $11,720,000 $2,609,000 +$2,149,000 +467% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $9,571,000 $2,098,000 +$1,742,000 +489% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $7,829,000 $2,250,000 +$1,986,000 +752% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $5,843,000 $4,763,000 +$15,968,000 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $10,125,000 $460,000 -$4,559,000 -91% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $5,566,000 $356,000 -$4,374,000 -92% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $1,192,000 $264,000 -$4,021,000 -94% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $2,829,000 $11,205,000 -$13,479,000 -593% 01 Oct 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
Q3 2021 $16,308,000 $5,019,000 +$4,828,000 +2528% 01 Jul 2021 30 Sep 2021 10-Q 02 Nov 2022 2022 Q3
Q2 2021 $11,480,000 $4,730,000 +$4,602,000 +3595% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $6,878,000 $4,285,000 +$4,238,000 +9017% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $2,640,000 $2,274,000 01 Oct 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
Q3 2020 $191,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $128,000 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $47,000 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1

ARS Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $14,534,000 +$5,299,000 +57% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
2023 $9,235,000 +$3,392,000 +58% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
2022 $5,843,000 +$3,014,000 +107% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $2,829,000 +$189,000 +7.2% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
2020 $2,640,000 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.